Page 81 - HIVMED_v21_i1.indb

Page 8 of 8 Guideline

9. Kibengo FM, Ruzagira E, Katende D, et al. Safety, adherence and acceptability of 28. Fonsart J, Saragosti S, Taouk M, et al. Single-dose pharmacokinetics and
intermittent tenofovir/emtricitabine as HIV pre-exposure prophylaxis (PrEP) pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal
among HIV-uninfected Ugandan volunteers living in HIV-serodiscordant tissue: A sub-study of the ANRS IPERGAY trial. J Antimicrob Chemother.
relationships: A randomized, clinical trial. PLoS One. 2013;8(9):e74314. https:// 2017;72(2):478–485. https://doi.org/10.1093/jac/dkw412
doi.org/10.1371/journal.pone.0074314 29. Hanscom B, Janes HE, Guarino PD, et al. Brief report: Preventing HIV-1 infection in
10. Khamsi R. PrEP trial successes prompt cost-effectiveness questions. Nat Med. women using oral preexposure prophylaxis: A meta-analysis of current evidence.
2011;17(9):1028. https://doi.org/10.1038/nm0911-1028b J Acquir Immune Defic Syndr. 2016;73(5):606–608. https://doi.org/10.1097/
11. Corneli AL, Deese J, Wang M, et al. FEM-PrEP: Adherence Patterns and Factors QAI.0000000000001160
Associated With Adherence to a Daily Oral Study Product for Pre-exposure 30. Graybill LA, Kasaro M, Freeborn K, et al. Incident HIV among pregnant and
Prophylaxis. J Acquir Immune Defic Syndr. 2014;66(3):324–331. https://doi. breast-feeding women in sub-Saharan Africa: A systematic review and meta-
org/10.1097/QAI.0000000000000158 analysis. AIDS. 2020;34(5):761–776. https://doi.org/10.1097/QAD.00000000
12. Haberer JE, Bangsberg DR, Baeten JM, et al. Defining success with HIV pre- 00002487
exposure prophylaxis: A prevention-effective adherence paradigm. AIDS. 31. Heffron R, Ngure K, Odoyo J, et al. Pre-exposure prophylaxis for HIV-negative
2015;29(11):1277–1285. https://doi.org/10.1097/QAD.0000000000000647 persons with partners living with HIV: Uptake, use, and effectiveness in an open-
13. Jewell BL, Cremin I, Pickles M, et al. Estimating the cost-effectiveness of pre- label demonstration project in East Africa. Gates Open Res. 2017;1:3. https://doi.
org/10.12688/gatesopenres.12752.1
exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant
couples in South Africa. PLoS One. 2015;10(1):e0115511. https://doi.org/10.1371/ 32. Schwartz SR, West N, Phofa R, et al. Acceptability and preferences for safer
journal.pone.0115511 conception HIV prevention strategies: A qualitative study. Int J STD AIDS.
14. Ying R, Sharma M, Heffron R, et al. Cost-effectiveness of pre-exposure prophylaxis 2015;27(11):984–992. https://doi.org/10.1177/0956462415604091
targeted to high-risk serodiscordant couples as a bridge to sustained ART use in 33. Schwartz SR, Bassett J, Sanne I, Phofa R, Yende N, Van Rie A. Implementation
Kampala, Uganda. J Int AIDS Soc. 2015;18(4 Suppl 3):20013. https://doi. of a safer conception service for HIV-affected couples in South Africa. AIDS.
org/10.7448/IAS.18.4.20013 2014;28(Suppl 3):S277–S285. https://doi.org/10.1097/QAD.000000000000
15. Baeten JM, Heffron R, Kidoguchi L, et al. Integrated delivery of antiretroviral 0330
treatment and pre-exposure prophylaxis to HIV-1-serodiscordant couples: A 34. Davies NE, Matthews LT, Crankshaw TL, Cooper D, Schwartz SR. Supporting HIV
prospective implementation study in Kenya and Uganda. PLoS Med. prevention and reproductive goals in an HIV-endemic setting: Taking safer
2016;13(8):e1002099. https://doi.org/10.1371/journal.pmed.1002099 conception services from policy to practice in South Africa. J Int AIDS Soc.
16. Mugwanya KK, Baeten JM. Safety of oral tenofovir disoproxil fumarate-based 2017;20(Suppl 1):21271. https://doi.org/10.7448/IAS.20.2.21271
pre-exposure prophylaxis for HIV prevention. Expert Opin Drug Saf. 35. Davies NECG, Schwartz S. Uptake and clinical outcomes from a primary healthcare
2016;15(2):265–273. https://doi.org/10.1517/14740338.2016.1128412 based safer conception service in Johannesburg, South Africa: Findings at 7 months
17. Heffron R, McClelland RS, Balkus JE, et al. Efficacy of oral pre-exposure prophylaxis International AIDS Society Conference; 2018 July 18; Durban, South Africa.
(PrEP) for HIV among women with abnormal vaginal microbiota: A post-hoc 36. Kojima N, Davey DJ, Klausner JD. Pre-exposure prophylaxis for HIV infection and
analysis of the randomised, placebo-controlled Partners PrEP Study. Lancet HIV. new sexually transmitted infections among men who have sex with men. AIDS.
2017;4(10):e449–e456. https://doi.org/10.1016/S2352-3018(17)30110-8 2016;30(14):2251–2252. https://doi.org/10.1097/QAD.0000000000001185
18. Mugwanya KK, John-Stewart G, Baeten J. Safety of oral tenofovir disoproxil 37. Freeborn K, Portillo CJ. Does pre-exposure prophylaxis for HIV prevention in men
fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected who have sex with men change risk behaviour? A systematic review. J Clin Nurs.
women. Expert Opin Drug Saf. 2017;16(7):867–871. https://doi.org/10.1080/147 2018;27(17–18):3254–3265. https://doi.org/10.1111/jocn.13990
40338.2017.1338271
19. Joseph Davey DL, Pintye J, Baeten JM, et al. Emerging evidence from a systematic 38. Joseph Davey D, Peters RPH, Kojima N, et al. Sexual behaviors of human
immunodeficiency virus-infected pregnant women and factors associated
review of safety of pre-exposure prophylaxis for pregnant and postpartum with sexually transmitted infection in South Africa. Sex Transm Dis.
women: Where are we now and where are we heading? J Int AIDS Soc. 2018;45(11):754–761. https://doi.org/10.1097/OLQ.0000000000000847
2020;23(1):e25426. https://doi.org/10.1002/jia2.25426
39. Joseph Davey DL, Nyemba DC, Gomba Y, et al. Prevalence and correlates of
20. UNAIDS. UNAIDS Data 2019. Geneva: The Joint United Nations Programme on sexually transmitted infections in pregnancy in HIV-infected and- uninfected
HIV/AIDS (UNAIDS); 2019. women in Cape Town, South Africa. PLoS One. 2019;14(7):e0218349. https://doi.
21. AIDS Vaccine Advocacy Coalition. PrEP watch, South Africa. ‘A Snapshot of PrEP org/10.1371/journal.pone.0218349
scale up, registration and resources for South Africa’ [document on the Internet]. 40. Morikawa E, Mudau M, Olivier D, et al. Acceptability and feasibility of integrating
2020 [cited 2020 Jun 02]. point-of-care diagnostic testing of sexually transmitted infections into a South
22. Balzer L, Staples P, Onnela JP, DeGruttola V. Using a network-based approach and African antenatal care program for HIV-infected pregnant women. Infect Dis
targeted maximum likelihood estimation to evaluate the effect of adding pre- Obstet Gynecol. 2018;2018:3946862. https://doi.org/10.1155/2018/3946862
exposure prophylaxis to an ongoing test-and-treat trial. Clin Trials. 41. Molina J-M, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men
2017;14(2):201–210. https://doi.org/10.1177/1740774516679666 at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–2246. https://
23. Flynn PM, Mirochnick M, Shapiro DE, et al. Pharmacokinetics and safety of single- doi.org/10.1056/NEJMoa1506273
dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant 42. Hare B. The phase 3 discover study: Daily F/TAF or F/TDF for HIV preexposure
women and their infants. Antimicrob Agents Chemother. 2011;55(12):5914–5922. prophylaxis. Conference on retroviruses and opportunistic infections; CROI 2019
https://doi.org/10.1128/AAC.00544-11
March 4-7; Seattle, Washington, USA.
24. World Health Organization. WHO expands recommendation on oral pre-exposure 43. HIV Prevention Trials Network. A phase 2b/3 double blind safety and efficacy study
prophylaxis of HIV infection (PrEP), WHO policy brief. World Health Organization; of injectable cabotegravir compared to daily oral tenofovir disoproxil fumarate/
2014. emtricitabine (TDF/FTC), for pre-exposure prophylaxis in HIV-uninfected cisgender
25. Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal men and transgender women who have sex with men [homepage on the Internet].
transmission for HIV-infected pregnant women and their infants. J Acquir Immune 2020 [cited 2020 Jul 06]. https://www.hptn.org/news-and-events/press-releases/
Defic Syndr. 2002;30(2):200–215. https://doi.org/10.1097/00042560-200206010- hptn-083-study-demonstrates-superiority-cabotegravir-prevention-hiv
00010 44. Vaginal ring to reduce the risk of HIV infection for women in non-EU countries
26. Antoni G, Tremblay C, Delaugerre C, et al. On-demand pre-exposure prophylaxis with high disease burden [homepage on the Internet]. EMA press release.
with tenofovir disoproxil fumarate plus emtricitabine among men who have sex [cited 2020 Aug 09]. Available from: https://www.ema.europa.eu/en/news/
with men with less frequent sexual intercourse: A post-hoc analysis of the ANRS vaginal-ring-reduce-risk-hiv-infection-women-non-eu-countries-high-disease-
IPERGAY trial. Lancet HIV. 2020;7(2):e113–e120. https://doi.org/10.1016/s2352- burden
3018(19)30341-8
45. Grant RM, Pellegrini M, Defechereux PA, et al. Sex hormone therapy and tenofovir
27. Cambou MC, Landovitz RJ. Novel antiretroviral agents. Curr HIV/AIDS Rep. diphosphate concentration in dried blood spots: Primary results of the iBrEATHe
2020;17(2):118–124. https://doi.org/10.1007/s11904-020-00486-2 study. Clin Infect Dis. ciaa1160. https://doi.org/10.1093/cid/ciaa1160

http://www.sajhivmed.org.za 73 Open Access